SG11202105626TA - Oligonucleotide compositions and methods thereof - Google Patents
Oligonucleotide compositions and methods thereofInfo
- Publication number
- SG11202105626TA SG11202105626TA SG11202105626TA SG11202105626TA SG11202105626TA SG 11202105626T A SG11202105626T A SG 11202105626TA SG 11202105626T A SG11202105626T A SG 11202105626TA SG 11202105626T A SG11202105626T A SG 11202105626TA SG 11202105626T A SG11202105626T A SG 11202105626TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776432P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/027109 WO2019200185A1 (en) | 2018-04-12 | 2019-04-11 | Oligonucleotide compositions and methods of use thereof |
| PCT/US2019/031672 WO2019217784A1 (en) | 2018-05-11 | 2019-05-10 | Oligonucleotide compositions and methods of use thereof |
| US201962916194P | 2019-10-16 | 2019-10-16 | |
| US201962916192P | 2019-10-16 | 2019-10-16 | |
| PCT/US2019/065058 WO2020118246A1 (en) | 2018-12-06 | 2019-12-06 | Oligonucleotide compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105626TA true SG11202105626TA (en) | 2021-06-29 |
Family
ID=70973999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105626TA SG11202105626TA (en) | 2018-12-06 | 2019-12-06 | Oligonucleotide compositions and methods thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220186217A1 (en) |
| EP (1) | EP3891284A4 (en) |
| JP (1) | JP2022513719A (en) |
| CN (1) | CN113383078A (en) |
| AU (1) | AU2019392928A1 (en) |
| CA (1) | CA3122271A1 (en) |
| SG (1) | SG11202105626TA (en) |
| WO (1) | WO2020118246A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015000784A8 (en) | 2012-07-13 | 2018-04-03 | Wave Life Sciences Japan | ASYMMETRICAL AUXILIARY GROUP |
| EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| CA3015823A1 (en) | 2016-03-13 | 2017-09-21 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| MA45188A (en) | 2016-06-03 | 2019-04-10 | Wave Life Sciences Ltd | OLIGONUCLEOTIDES, ASSOCIATED COMPOSITIONS AND METHODS |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CN110996968A (en) | 2017-08-08 | 2020-04-10 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods thereof |
| SG11202000276YA (en) | 2017-09-18 | 2020-04-29 | Wave Life Sciences Ltd | Technologies for oligonucleotide preparation |
| US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2020191252A1 (en) * | 2019-03-20 | 2020-09-24 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| WO2023154528A1 (en) * | 2022-02-11 | 2023-08-17 | Wave Life Sciences Ltd. | Stereoselective technologies for chiral compounds |
| WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617442B1 (en) * | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| AU2002362312A1 (en) * | 2001-09-17 | 2003-04-01 | Mayo Foundation For Medical Education And Research | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| WO2009054725A2 (en) * | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| AU2009310557B2 (en) * | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
| WO2011109427A2 (en) * | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
| EP2872147B1 (en) * | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| KR20230152178A (en) * | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
| AU2015227733B2 (en) * | 2014-03-12 | 2019-10-31 | National Center Of Neurology And Psychiatry | Antisense nucleic acids |
| RU2708237C2 (en) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Modified oligonucleotides and method for production thereof |
| EP3858993A1 (en) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| MX2018003992A (en) * | 2015-10-09 | 2018-08-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof. |
-
2019
- 2019-12-06 CA CA3122271A patent/CA3122271A1/en active Pending
- 2019-12-06 JP JP2021531966A patent/JP2022513719A/en active Pending
- 2019-12-06 AU AU2019392928A patent/AU2019392928A1/en active Pending
- 2019-12-06 CN CN201980090833.2A patent/CN113383078A/en active Pending
- 2019-12-06 WO PCT/US2019/065058 patent/WO2020118246A1/en unknown
- 2019-12-06 SG SG11202105626TA patent/SG11202105626TA/en unknown
- 2019-12-06 EP EP19891722.1A patent/EP3891284A4/en active Pending
- 2019-12-06 US US17/311,285 patent/US20220186217A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220186217A1 (en) | 2022-06-16 |
| AU2019392928A1 (en) | 2021-06-17 |
| JP2022513719A (en) | 2022-02-09 |
| CN113383078A (en) | 2021-09-10 |
| WO2020118246A1 (en) | 2020-06-11 |
| EP3891284A1 (en) | 2021-10-13 |
| EP3891284A4 (en) | 2023-04-12 |
| CA3122271A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
| IL284882A (en) | Oligonucleotide compositions and methods thereof | |
| SG11202001783YA (en) | Oligonucleotide compositions and methods thereof | |
| EP3664815A4 (en) | Oligonucleotide compositions and methods thereof | |
| IL277889A (en) | Oligonucleotide compositions and methods of use thereof | |
| HK1256225A1 (en) | Oligonucleotide compositions and methods thereof | |
| HK1255369A1 (en) | Oligonucleotide compositions and methods thereof | |
| IL277079A (en) | Cartyrin compositions and methods for use | |
| IL280134A (en) | Anti-cd112r compositions and methods | |
| EP3452596A4 (en) | Oligonucleotide compositions and methods thereof | |
| SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
| IL268970A (en) | Novel compositions and methods | |
| GB201807325D0 (en) | Compositions and methods | |
| GB202201861D0 (en) | Novel methods and compositions | |
| SG11202104448WA (en) | Compositions and methods | |
| GB201815402D0 (en) | Compositions and methods and uses relating thereto | |
| GB201913204D0 (en) | Compositions and methods and uses relating thereto | |
| GB201817444D0 (en) | Methods and compositions | |
| ZA202004533B (en) | Skin-brightening compositions and methods | |
| GB201819987D0 (en) | Methods and compositions | |
| SG11202108262VA (en) | Bacterialcidal methods and compositions | |
| GB201817902D0 (en) | Methods and compositions | |
| GB201809880D0 (en) | Compositions and methods | |
| GB201804092D0 (en) | Methods and compositions | |
| GB201917066D0 (en) | Methods and compositions |